Last reviewed · How we verify

Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting

Azad University of Medical Sciences · FDA-approved active Small molecule

This is a multimodal treatment combining corticosteroid anti-inflammation (triamcinolone acetonide), nonsteroidal anti-inflammatory action (indomethacin), localized tissue destruction (cryotherapy), and mechanical immobilization (casting) for musculoskeletal or orthopedic conditions.

This is a multimodal treatment combining corticosteroid anti-inflammation (triamcinolone acetonide), nonsteroidal anti-inflammatory action (indomethacin), localized tissue destruction (cryotherapy), and mechanical immobilization (casting) for musculoskeletal or orthopedic conditions. Used for Musculoskeletal inflammatory conditions requiring local anti-inflammatory and immobilization therapy.

At a glance

Generic nameTriamcinolone Acetonide- Indomethacin-Cryotherapy-Casting
SponsorAzad University of Medical Sciences
ModalitySmall molecule
Therapeutic areaOrthopedics/Rheumatology
PhaseFDA-approved

Mechanism of action

Triamcinolone acetonide reduces inflammation via glucocorticoid receptor activation. Indomethacin inhibits prostaglandin synthesis to further suppress inflammation and pain. Cryotherapy induces localized tissue necrosis and reduces metabolic activity in the treated area. Casting provides mechanical stabilization and immobilization to prevent further injury and promote healing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: